Galiximab
Based on 1 publication(s) in Google Scholar
Galiximab (IDEC-114) is a primatized monoclonal IgG1 antibody targeting CD80. Galiximab variable regions are primatized, and the constant regions are humanized. Galiximab induces antibody-dependent cellular cytotoxicity by blocking CD80-CD28 binding. Galiximab has antitumor activity and can induce apoptosis in tumor cells. Galiximab can be used in the research of relapsed Hodgkin lymphoma and solid tumors.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.23%
- CAS 番号: 357613-77-5
- 分子量:145.24 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Galiximab
More
生物活性
Human IgG1 lambda
Human
CD28L/CD80
Galiximab (25-100 μg/mL; 36 h) in combination with Doxorubicin (HY-15142A) significantly enhances apoptosis in Raji cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Raji cells treated Doxorubicin (HY-15142A) (0.05-1 µg/mL)
-
Concentration:25, 50 and 100 μg/mL
-
Incubation Time:36 h
-
Result:Enhanced cell apoptosis in a dose-dependent manner.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female CB17 SCID mice aged 6-8 weeks old treated Raji cells or SKW6.4 cells[1]
-
Dosage:Raji model: 0.1, 1, 3, 10, 30 mg/kg; once weekly; 3 times in total
SKW6.4 model: 5, 10, 30 mg/kg; once weekly; 4 times in total -
Administration:Intraperitoneal injection
-
Result:Showed dose-dependent tumor growth inhibition and survival prolongation in both models.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 lambda
ELISA, FACS, Functional assay
-
Flow Cytometry analysis of Raji cells labelling CD28L/CD80 (red) with Galiximab (anti-CD28L/CD80) (HY-P99293). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
化学情報
-
CAS 番号 357613-77-5
-
性状 Liquid
-
分子量 145.24 kDa
-
Color Colorless to light yellow
-
SMILES
[Galiximab]
-
別名
IDEC 114; Anti-Human CD80 Recombinant Antibody
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Sci Rep
CD80 (B7-1) as a potential therapeutic target in Epstein-Barr virus‑associated B cell diseases. [Abstract]2026 May 26. PMID: 42191836
純度とドキュメンテーション
-
データシート (260 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Hariharan K, et al. Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine. Int J Oncol. 2013 Aug;43(2):670-6. [Content Brief]
[2]. Smith SM, et, al. The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). Leuk Lymphoma. 2013 Jul;54(7):1405-10. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Galiximab 関連分類
HY-P99293 関連分類
Powered by Bioz